NAME OF DRUG : GS0976
LABORATORY : GILEAD
STATUS AND ADVANCEMENT
Type of drug : ACC inhibitor
Clinical trials advancement : Ongoing Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated time to market : 92 months.
LABORATORY ABSTRACT ON THE DRUG
Acetyl-CoA carboxylase (ACC) is an enzyme with two isoforms (ACC1 and ACC2) that is involved in de novo lipogenesis (the synthesis of endogenous fatty acids) and the regulation of beta-oxidation (the process by which fatty acids are broken down at a cellular level). Inhibitors of ACC, therefore, have the potential to prevent production of new lipids within the liver and stimulate their breakdown. In animal models of fatty liver, ACC inhibition reduces hepatic fat content, inflammation and fibrosis (scarring), all of which are important hallmarks of NASH progression. NDI-010976 is a potent, liver-targeted, allosteric inhibitor of both ACC isoforms. NDI-010976 (now GS-0976) is an investigational therapy and has not been proven safe or efficacious.
HISTORY AND ANALYSIS
This medication was purchased by GILEAD from NIMBUS in their APOLLO program.
Comments have been made on the galenic kinetics of this drug which has a fairly short half-life in the body as shown in the following graph.
The results of the Phase 1 conducted by NIMBUS are available on the following poster
RECENT NEWS ON GS0976
SOME PUBLICATIONS RELATED WITH GS0976
April 2017 : Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects
SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH GS0976
October 2016 : NASH COMBOs ARE THE WAY